Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combination strategies, in the treatment of ER+/HER2− metastatic breast cancer. Drs. Jhaveri and Kaklamani review emerging efficacy and safety data, considerations for treatment selection after prior endocrine therapy and CDK4/6 inhibitor exposure, the role of ESR1 mutation testing in sequencing therapy, and emerging combination and frontline treatment data. The discussion also highlights practical, interdisciplinary approaches to monitoring and managing adverse events to support evidence-based clinical decision-making in practice.
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
4
episodes
29m
Details
Presenters
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, AXIS Medical Education requires all faculty and planners to disclose financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated to ensure that the content is free from commercial bias.
The following faculty and planners have disclosed relevant financial relationships with ineligible companies in the past 24 months.
Chair:
Komal Jhaveri, MD, FACP
Associate Attending Physician
Breast Medicine Service/Dept of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Research: AstraZeneca, Bicycle Therapeutics, Blueprint Medicines, Breast Cancer Research Foundation, BridgeBio Oncology Therapeutics, Eisai, Fred’s Team and Manhasset Women’s Coalition Against Breast Cancer (paid to institution), Genentech, Gilead, Lilly/Loxo Oncology, Merck Pharmaceuticals, Novartis, Pfizer, PUMA Biotechnology, Rayzebio, Scorpion Therapeutics, Zymeworks
Consulting Fees: Arivinas, AstraZeneca, BeOneTherapeutics, Bicycle Therapeutics, Blueprint Medicines, BridgeBio Oncology Therapeutics, ConcertAI, Daiichi Sankyo, Eisai, Genentech, Gilead, Halda Therapeutics, Lilly/Loxo Oncology, Merck Pharmaceuticals, Mersana, Natera, Novartis, Olema Pharmaceuticals, Pfizer, Precede Biosciences, Rayzebio, Relay Pharmaceuticals, Scorpion Therapeutics, Zymeworks
Faculty:
Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer
UT Health San Antonio, MD Anderson Cancer Center
San Antonio, TX
Consultant Fees: AstraZeneca, Daiichi, Genentech, Gilead, Menarini Pharma
Research: Eisai
Reviewers/Planners/Authors:- Tim Person has no relevant relationships to disclose.
- Jocelyn Timko has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Compare emerging efficacy and safety data for oral SERDs, including PROTACs and novel combinations, to inform evidence-based clinical decisions in ER+/HER2− mBC
- Assess current considerations for treatment selection in ER+/HER2− mBC, including the use of oral SERDs such as PROTACs in patients with prior ET and CDK4/6 inhibitor exposure
- Evaluate clinical strategies that take ESR1 mutations into account when sequencing oral SERDs, including PROTACs and other targeted therapies, in ER+/HER2− mBC
- Describe interdisciplinary strategies for monitoring and managing AEs associated with oral SERDs and PROTACs in the treatment of ER+/HER2− mBC
Target Audience
This activity has been designed to meet the educational needs of oncologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with ER+/HER2− mBC.
Accreditation and Credit Designation Statements
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AXIS Medical Education, Inc. (AXIS) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AXIS Medical Education, Inc. (AXIS) designates this activity for 0.50 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
AXIS designates this activity for 0.50 contact hour(s)/0.05 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-26-112-H01-P. This learning activity is knowledge based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
AXIS has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit(s). Approval is valid until 08/28/27. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
AXIS Medical Education, Inc. is a full-service continuing education company that designs and implements live, digital, and print-based educational activities for healthcare professionals. AXIS provides convenient opportunities to engage learners based on their individual learning preferences through a full spectrum of educational offerings.Commercial Support
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals, Lilly, Rigel Pharmaceuticals, Inc., and Stemline Therapeutics, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of AXIS. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
